Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies

A report from Japan marrow donor program

Y. Inamoto, K. Miyamura, Shinichiro Okamoto, H. Akiyama, H. Iida, T. Eto, Y. Morishima, K. Kawa, A. Kikuchi, Y. Nagatoshi, J. Tanaka, T. Ashida, M. Hirokawa, M. Tsuchida, S. Mori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cell dose is one of the major factors that can be manipulated in unrelated BMT. However, regarding disease-stage-stratified effects of cell dose, data are limited. We analyzed the registry data from 3559 patients with acute leukemia, CML and myelodysplastic syndrome who received T-cell replete unrelated BMT through the Japan Marrow Donor Program. Adjusted effects of cell dose were evaluated for various outcomes separately according to disease stages and children or adults. Acute GVHD and nonrelapse mortality were not affected by cell dose. Among children, a cell dose lower than 3.0 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. Among adults, a cell dose of 3.4 × 10 8/kg or higher was associated with lower relapse rates and better survival rates only in early-stage diseases, whereas cell dose below 2.3 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. In conclusion, effects of cell dose may differ among disease stages. A cell dose of 3.4 × 10 8/kg or higher is recommended only for adults with early-stage diseases. With the number of patients available for analysis in this study, we could not show any significant benefits associated with 4.6 × 10 8/kg or higher in children.

Original languageEnglish
Pages (from-to)1192-1202
Number of pages11
JournalBone Marrow Transplantation
Volume46
Issue number9
DOIs
Publication statusPublished - 2011 Sep

Fingerprint

Hematologic Neoplasms
Japan
Bone Marrow
Tissue Donors
Myelodysplastic Syndromes
Registries
Leukemia
Survival Rate
T-Lymphocytes
Recurrence
Mortality

Keywords

  • allogeneic
  • cell dose
  • disease stage
  • unrelated

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies : A report from Japan marrow donor program. / Inamoto, Y.; Miyamura, K.; Okamoto, Shinichiro; Akiyama, H.; Iida, H.; Eto, T.; Morishima, Y.; Kawa, K.; Kikuchi, A.; Nagatoshi, Y.; Tanaka, J.; Ashida, T.; Hirokawa, M.; Tsuchida, M.; Mori, S.

In: Bone Marrow Transplantation, Vol. 46, No. 9, 09.2011, p. 1192-1202.

Research output: Contribution to journalArticle

Inamoto, Y, Miyamura, K, Okamoto, S, Akiyama, H, Iida, H, Eto, T, Morishima, Y, Kawa, K, Kikuchi, A, Nagatoshi, Y, Tanaka, J, Ashida, T, Hirokawa, M, Tsuchida, M & Mori, S 2011, 'Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: A report from Japan marrow donor program', Bone Marrow Transplantation, vol. 46, no. 9, pp. 1192-1202. https://doi.org/10.1038/bmt.2010.281
Inamoto, Y. ; Miyamura, K. ; Okamoto, Shinichiro ; Akiyama, H. ; Iida, H. ; Eto, T. ; Morishima, Y. ; Kawa, K. ; Kikuchi, A. ; Nagatoshi, Y. ; Tanaka, J. ; Ashida, T. ; Hirokawa, M. ; Tsuchida, M. ; Mori, S. / Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies : A report from Japan marrow donor program. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 9. pp. 1192-1202.
@article{df0c4da762614ed9b6153ffb75042953,
title = "Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: A report from Japan marrow donor program",
abstract = "Cell dose is one of the major factors that can be manipulated in unrelated BMT. However, regarding disease-stage-stratified effects of cell dose, data are limited. We analyzed the registry data from 3559 patients with acute leukemia, CML and myelodysplastic syndrome who received T-cell replete unrelated BMT through the Japan Marrow Donor Program. Adjusted effects of cell dose were evaluated for various outcomes separately according to disease stages and children or adults. Acute GVHD and nonrelapse mortality were not affected by cell dose. Among children, a cell dose lower than 3.0 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. Among adults, a cell dose of 3.4 × 10 8/kg or higher was associated with lower relapse rates and better survival rates only in early-stage diseases, whereas cell dose below 2.3 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. In conclusion, effects of cell dose may differ among disease stages. A cell dose of 3.4 × 10 8/kg or higher is recommended only for adults with early-stage diseases. With the number of patients available for analysis in this study, we could not show any significant benefits associated with 4.6 × 10 8/kg or higher in children.",
keywords = "allogeneic, cell dose, disease stage, unrelated",
author = "Y. Inamoto and K. Miyamura and Shinichiro Okamoto and H. Akiyama and H. Iida and T. Eto and Y. Morishima and K. Kawa and A. Kikuchi and Y. Nagatoshi and J. Tanaka and T. Ashida and M. Hirokawa and M. Tsuchida and S. Mori",
year = "2011",
month = "9",
doi = "10.1038/bmt.2010.281",
language = "English",
volume = "46",
pages = "1192--1202",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies

T2 - A report from Japan marrow donor program

AU - Inamoto, Y.

AU - Miyamura, K.

AU - Okamoto, Shinichiro

AU - Akiyama, H.

AU - Iida, H.

AU - Eto, T.

AU - Morishima, Y.

AU - Kawa, K.

AU - Kikuchi, A.

AU - Nagatoshi, Y.

AU - Tanaka, J.

AU - Ashida, T.

AU - Hirokawa, M.

AU - Tsuchida, M.

AU - Mori, S.

PY - 2011/9

Y1 - 2011/9

N2 - Cell dose is one of the major factors that can be manipulated in unrelated BMT. However, regarding disease-stage-stratified effects of cell dose, data are limited. We analyzed the registry data from 3559 patients with acute leukemia, CML and myelodysplastic syndrome who received T-cell replete unrelated BMT through the Japan Marrow Donor Program. Adjusted effects of cell dose were evaluated for various outcomes separately according to disease stages and children or adults. Acute GVHD and nonrelapse mortality were not affected by cell dose. Among children, a cell dose lower than 3.0 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. Among adults, a cell dose of 3.4 × 10 8/kg or higher was associated with lower relapse rates and better survival rates only in early-stage diseases, whereas cell dose below 2.3 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. In conclusion, effects of cell dose may differ among disease stages. A cell dose of 3.4 × 10 8/kg or higher is recommended only for adults with early-stage diseases. With the number of patients available for analysis in this study, we could not show any significant benefits associated with 4.6 × 10 8/kg or higher in children.

AB - Cell dose is one of the major factors that can be manipulated in unrelated BMT. However, regarding disease-stage-stratified effects of cell dose, data are limited. We analyzed the registry data from 3559 patients with acute leukemia, CML and myelodysplastic syndrome who received T-cell replete unrelated BMT through the Japan Marrow Donor Program. Adjusted effects of cell dose were evaluated for various outcomes separately according to disease stages and children or adults. Acute GVHD and nonrelapse mortality were not affected by cell dose. Among children, a cell dose lower than 3.0 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. Among adults, a cell dose of 3.4 × 10 8/kg or higher was associated with lower relapse rates and better survival rates only in early-stage diseases, whereas cell dose below 2.3 × 10 8/kg was associated with lower engraftment rates in advanced-stage diseases. In conclusion, effects of cell dose may differ among disease stages. A cell dose of 3.4 × 10 8/kg or higher is recommended only for adults with early-stage diseases. With the number of patients available for analysis in this study, we could not show any significant benefits associated with 4.6 × 10 8/kg or higher in children.

KW - allogeneic

KW - cell dose

KW - disease stage

KW - unrelated

UR - http://www.scopus.com/inward/record.url?scp=80052445981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052445981&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.281

DO - 10.1038/bmt.2010.281

M3 - Article

VL - 46

SP - 1192

EP - 1202

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -